ADAM Proteins

DBCAT005841Pharmacologic class

A family of membrane-anchored glycoproteins that contain a disintegrin and metalloprotease domain. They are responsible for the proteolytic cleavage of many transmembrane proteins and the release of their extracellular domain. A DrugBank category of 1 drug. 1 of them is approved.

Drugs: Apadamtase alfa

What you can answer from here — as of April 30, 2023

1DrugEach linked to its full drug card

Listed above

2Drug targetsEvery drug–target pair in the class, with bond type

4Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do ADAM Proteins share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account